Latest Lion Point Capital, LP Stock Portfolio
Lion Point Capital, LP Performance:
2025 Q3: 19.27%YTD: 5.31%2024: -31.55%
Performance for 2025 Q3 is 19.27%, and YTD is 5.31%, and 2024 is -31.55%.
About Lion Point Capital, LP and 13F Hedge Fund Stock Holdings
In it's latest 13F Holdings report, Lion Point Capital, LP reported an equity portfolio of $17.6 Millions as of 30 Sep, 2025.
The top stock holdings of Lion Point Capital, LP are , MIST, FENC. The fund has invested 8.4% of it's portfolio in MINERALYS THERAPEUTICS INC and 7.5% of portfolio in MILESTONE PHARMACEUTICALS IN.
The fund managers got completely rid off MERSANA THERAPEUTICS INC (MRSN) stocks. They significantly reduced their stock positions in ARDELYX INC (ARDX), MINERALYS THERAPEUTICS INC and BRIDGEBIO PHARMA INC (BBIO). Lion Point Capital, LP opened new stock positions in ROYALTY PHARMA PLC (RPRX), MOONLAKE IMMUNOTHERAPEUTICS (MLTX) and KURA ONCOLOGY INC (KURA). The fund showed a lot of confidence in some stocks as they added substantially to JASPER THERAPEUTICS INC (JSPR), SERES THERAPEUTICS INC (MCRB) and MILESTONE PHARMACEUTICALS IN (MIST).
The top stock holdings of Lion Point Capital, LP are , MIST, FENC. The fund has invested 8.4% of it's portfolio in MINERALYS THERAPEUTICS INC and 7.5% of portfolio in MILESTONE PHARMACEUTICALS IN.
The fund managers got completely rid off MERSANA THERAPEUTICS INC (MRSN) stocks. They significantly reduced their stock positions in ARDELYX INC (ARDX), MINERALYS THERAPEUTICS INC and BRIDGEBIO PHARMA INC (BBIO). Lion Point Capital, LP opened new stock positions in ROYALTY PHARMA PLC (RPRX), MOONLAKE IMMUNOTHERAPEUTICS (MLTX) and KURA ONCOLOGY INC (KURA). The fund showed a lot of confidence in some stocks as they added substantially to JASPER THERAPEUTICS INC (JSPR), SERES THERAPEUTICS INC (MCRB) and MILESTONE PHARMACEUTICALS IN (MIST).
Lion Point Capital, LP Annual Return Estimates Vs S&P 500
Our best estimate is that Lion Point Capital, LP made a return of 19.27% in the last quarter. In trailing 12 months, it's portfolio return was 2.56%.
New Buys
| Ticker | $ Bought |
|---|---|
| royalty pharma plc | 754,992 |
| moonlake immunotherapeutics | 483,975 |
| kura oncology inc | 407,100 |
| compass pathways plc | 332,340 |
| praxis precision medicines i | 302,100 |
| day one biopharmaceuticals i | 296,100 |
| rocket pharmaceuticals inc | 280,360 |
| mersana therapeutics inc | 199,898 |
New stocks bought by Lion Point Capital, LP
Additions
| Ticker | % Inc. |
|---|---|
| jasper therapeutics inc | 172 |
| seres therapeutics inc | 59.28 |
| milestone pharmaceuticals in | 20.00 |
Additions to existing portfolio by Lion Point Capital, LP
Reductions
| Ticker | % Reduced |
|---|---|
| ardelyx inc | -51.48 |
| mineralys therapeutics inc | -50.63 |
| kiniksa pharmaceuticals intl | -49.02 |
| bridgebio pharma inc | -48.85 |
| insmed inc | -41.31 |
| avadel pharmaceuticals plc | -39.51 |
| fennec pharmaceuticals inc | -37.15 |
| arcutis biotherapeutics inc | -23.76 |
Lion Point Capital, LP reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| mersana therapeutics inc | -190,624 |
Lion Point Capital, LP got rid off the above stocks
Sector Distribution
Lion Point Capital, LP has about 75.3% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 75.3 |
| Others | 24.7 |
Market Cap. Distribution
Lion Point Capital, LP has about 9.4% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| MICRO-CAP | 28.5 |
| SMALL-CAP | 26.9 |
| UNALLOCATED | 24.7 |
| MID-CAP | 10.6 |
| LARGE-CAP | 9.4 |
Stocks belong to which Index?
About 46.8% of the stocks held by Lion Point Capital, LP either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| Others | 53.2 |
| RUSSELL 2000 | 46.8 |
Lion Point Capital, LP Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Lion Point Capital, LP
Lion Point Capital, LP has 27 stocks in it's portfolio. About 58.1% of the portfolio is in top 10 stocks. JSPR proved to be the most loss making stock for the portfolio. was the most profitable stock for Lion Point Capital, LP last quarter.
Last Reported on: 14 Nov, 2025| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ARDX | ardelyx inc | 5.10 | 162,750 | 896,753 | reduced | -51.48 | ||
| ARQT | arcutis biotherapeutics inc | 3.78 | 35,300 | 665,405 | reduced | -23.76 | ||
| BBIO | bridgebio pharma inc | 3.92 | 13,300 | 690,802 | reduced | -48.85 | ||
| BNTC | benitec biopharma inc | 4.94 | 62,000 | 869,860 | unchanged | 0.00 | ||
| CMPS | compass pathways plc | 1.89 | 58,000 | 332,340 | new | |||
| DAWN | day one biopharmaceuticals i | 1.68 | 42,000 | 296,100 | new | |||
| FENC | fennec pharmaceuticals inc | 6.54 | 123,000 | 1,151,280 | reduced | -37.15 | ||
| GERN | geron corp | 3.89 | 500,000 | 685,000 | unchanged | 0.00 | ||
| HUMA | humacyte inc | 0.82 | 83,500 | 145,290 | unchanged | 0.00 | ||
| INSM | insmed inc | 5.11 | 6,250 | 900,063 | reduced | -41.31 | ||
| JSPR | jasper therapeutics inc | 5.39 | 398,558 | 948,568 | added | 172 | ||
| KURA | kura oncology inc | 2.31 | 46,000 | 407,100 | new | |||
| MCRB | seres therapeutics inc | 2.97 | 27,138 | 522,135 | added | 59.28 | ||
| MIST | milestone pharmaceuticals in | 7.48 | 658,553 | 1,317,110 | added | 20.00 | ||
| MLTX | moonlake immunotherapeutics | 2.75 | 67,500 | 483,975 | new | |||
| MRSN | mersana therapeutics inc | 1.14 | 25,760 | 199,898 | new | |||
| MRSN | mersana therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| PRAX | praxis precision medicines i | 1.72 | 5,700 | 302,100 | new | |||
| RCKT | rocket pharmaceuticals inc | 1.59 | 86,000 | 280,360 | new | |||
| RGNX | regenxbio inc | 3.17 | 57,750 | 557,288 | unchanged | 0.00 | ||